AAPS PharmSciTech

, Volume 10, Issue 1, pp 166–171 | Cite as

Improving Tenoxicam Solubility and Bioavailability by Cosolvent System

  • Ming-Kung Yeh
  • Li-Chien Chang
  • Andy Hong-Jey Chiou
Research Article


The formulation study of tenoxicam, a poorly water-soluble drug, was developed by use of a ternary cosolvent system and has significantly enhanced the solubility. Additionally, the relative bioavailability of testing formulation was also evaluated by New Zealand rabbit with a single i.m. injection. The three-phase diagram for dimethylsulfoxide (DMSO)/propylene glycol/water, DMSO/ethanol/water, and DMSO/polyethoxylated castor oil/ethanol system was developed. The volume ratio of 5:4:1 in the DMSO/polyethoxylated castor oil/ethanol system resulted in a more suitable vehicle than other systems, with a high solubility (20.73 mg/ml) and low viscosity (10.0 Cp). A pharmacokinetic study of bioequivalence (F rel = 0.89) was also obtained. The present study not only provides a novel strategy improving tenoxicam solubility but also helps further scientific knowledge for the development of parenteral formulations.

Key words

bioavailability cosolvent system pharmacokinetics poorly water-soluble drug solubility tenoxicam 


  1. 1.
    C. Kim, Y. Y. Hwang, J. Y. Chang, H. G. Choi, S. J. Lim, and M. K. Lee. Development of a novel dosage form for intramuscular injection of titrated extract of Centella asiatica in a mixed micellar system. Int. J. Pharm. 220:141–147 (2001).PubMedCrossRefGoogle Scholar
  2. 2.
    A. Yoshida, M. Yamamoto, T. Irie, F. Hirayama, and K. Uekama. Some pharmaceutical properties of 3-hydroxypropyl- and 2,3-dihydroxypropyl-beta-cyclodextrins and their solubilizing and stabilizing abilities. Chem. Pharm. Bull. (Tokyo). 37:1059–1063 (1989).Google Scholar
  3. 3.
    P. Tilleul, B. Mons, C. Schmitt, J. M. Laporte, and D. Begue. Intravenous drug preparation practices: a survey in a French university hospital. Pharm. World Sci. 25:276–279 (2003).PubMedCrossRefGoogle Scholar
  4. 4.
    J. S. Trivedi, and M. L. Wells. Solubilization using cosolvent approach. Liu IR, (eds.), Water-Insoluble Drug Formulation, Interpharm, Denver, Colorado, 2000, pp. 141–168.Google Scholar
  5. 5.
    R. G. Strickley. Solubilizing excipients in oral and injectable formulations. Pharm. Res. 21:201–230 (2004).PubMedCrossRefGoogle Scholar
  6. 6.
    N. Seedher, and S. Bhatia. Solubility enhancement of Cox-2 inhibitors using various solvent systems. AAPS PharmSciTech. 4:E33 (2003).PubMedCrossRefGoogle Scholar
  7. 7.
    H. W. Hsu, Y. J. Cheng, L. K. Chen, Y. P. Wang, C. J. Lin, C. N. Lee, and W. Z. Sun. Differential analgesic effect of tenoxicam on the wound pain and uterine cramping pain after cesarean section. Clin. J. Pain. 19:55–58 (2003).PubMedCrossRefGoogle Scholar
  8. 8.
    J. L. Mason, and G. J. Hobbs. Simple method for the analysis of tenoxicam in human plasma using high-performance liquid chromatography. J. Chromatogr. B Biomed. Appl. 65:410–415 (1995).CrossRefGoogle Scholar
  9. 9.
    W. J. Loos, J. Szebeni, A. J. ten Tije, J. Verweij, D. M. van Zomeren, K. N. Chung, K. Nooter, G. Stoter, and A. Sparreboom. Preclinical evaluation of alternative pharmaceutical delivery vehicles for paclitaxel. Anticancer Drugs. 3:767–775 (2002).CrossRefGoogle Scholar
  10. 10.
    H. Liu, C. Sabus, G. T. Carter, C. Du, A. Avdeef, and M. Tischler. In vitro permeability of poorly aqueous soluble compounds using different solubilizers in the PAMPA assay with liquid chromatography/mass spectrometry detection. Pharm. Res. 20:1820–1826 (2003).PubMedCrossRefGoogle Scholar
  11. 11.
    B. K. Kang, J. S. Lee, S. K. Chon, S. Y. Jeong, S. H. Yuk, G. Khang, H. B. Lee, and S. H. Cho. Development of self-microemulsifying drug delivery systems (SMEDDS) for oral bioavailability enhancement of simvastatin in beagle dogs. Int. J. Pharm. 274:65–73 (2004).PubMedCrossRefGoogle Scholar
  12. 12.
    D. K. Lee, and D. P. Wang. Formulation development of allopurinol suppositories and injectables. Drug Dev. Ind. Pharm. 25:1205–1208 (1999).PubMedCrossRefGoogle Scholar
  13. 13.
    C. Udata, J. Patel, D. Pal, E. Hejchman, M. Cushman, and A. K. Mitra. Enhanced transport of a novel anti-HIV agent–cosalane and its congeners across human intestinal epithelial (Caco-2) cell monolayers. Int. J. Pharm. 250:157–168 (2003).PubMedCrossRefGoogle Scholar
  14. 14.
    K. Kawakami, K. Miyoshi, and Y. Ida. Solubilization behavior of poorly soluble drugs with combined use of Gelucire 44/14 and cosolvent. J. Pharm. Sci. 93:1471–1479 (2004).PubMedCrossRefGoogle Scholar
  15. 15.
    T. Stebler, and T. W. Guentert. Bioavailability of intramuscularly administered tenoxicam. Biopharm. Drug Dispos. 14:483–490 (1993).PubMedCrossRefGoogle Scholar
  16. 16.
    D. Chen, D. Song, M. G. Wientjes, and J. L. Au. Effect of dimethyl sulfoxide on bladder tissue penetration of intravesical paclitaxel. Clin. Cancer Res. 9:363–369 (2003).PubMedGoogle Scholar
  17. 17.
    G. Ehninger, U. Schuler, U. Renner, M. Ehrsam, K. P. Zeller, J. Blanz, R. Storb, and H. Deeg. Use of a water-soluble busulfan formulation–pharmacokinetic studies in a canine model. Blood. 85:3247–3249 (1995).PubMedGoogle Scholar
  18. 18.
    M. Hassan, Z. Hassan, C. Nilsson, M. A. Rehim, S. Kumlien, B. Elfsson, and N. Kallberg. Pharmacokinetics and distribution of liposomal busulfan in the rat: a new formulation for intravenous administration. Cancer. Chemother. Pharmacol. 42:471–478 (1998).PubMedCrossRefGoogle Scholar
  19. 19.
    U. S. Schuler, M. Ehrsam, A. Schneider, H. Schmidt, J. Deeg, and G. Ehninger. Pharmacokinetics of intravenous busulfan and evaluation of the bioavailability of the oral formulation in conditioning for haematopoietic stem cell transplantation. Bone Marrow Transplant. 22:241–244 (1998).PubMedCrossRefGoogle Scholar

Copyright information

© American Association of Pharmaceutical Scientists 2009

Authors and Affiliations

  • Ming-Kung Yeh
    • 1
  • Li-Chien Chang
    • 2
  • Andy Hong-Jey Chiou
    • 3
  1. 1.Department of Pharmacy PracticeTri-Service General HospitalTaipeiTaiwan
  2. 2.School of PharmacyNational Defense Medical CenterTaipeiTaiwan
  3. 3.Institute of Preventive MedicineNational Defense Medical CenterTaipeiRepublic of China

Personalised recommendations